Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.65 EUR
3.28 B EUR
8.91 B EUR
256.87 M
About Vertex Pharmaceuticals Incorporated
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
FIGI
BBG000GNZSN6
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 444.35 EUR — it has increased by 1.68% in the past 24 hours. Watch VERTEX PHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange VERTEX PHARMACEUTICAL stocks are traded under the ticker VX1.
VX1 stock has risen by 2.21% compared to the previous week, the month change is a 2.59% rise, over the last year VERTEX PHARMACEUTICAL has showed a 37.31% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICAL future price: according to them, VX1 price has a max estimate of 574.79 EUR and a min estimate of 310.31 EUR. Watch VX1 chart and read a more detailed VERTEX PHARMACEUTICAL stock forecast: see what analysts think of VERTEX PHARMACEUTICAL and suggest that you do with its stocks.
VX1 stock is 1.90% volatile and has beta coefficient of 1.29. Track VERTEX PHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICAL there?
Today VERTEX PHARMACEUTICAL has the market capitalization of 114.28 B, it has decreased by −2.68% over the last week.
Yes, you can track VERTEX PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICAL is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
VX1 earnings for the last quarter are 3.93 EUR per share, whereas the estimation was 3.66 EUR resulting in a 7.41% surprise. The estimated earnings for the next quarter are 3.84 EUR per share. See more details about VERTEX PHARMACEUTICAL earnings.
VERTEX PHARMACEUTICAL revenue for the last quarter amounts to 2.49 B EUR, despite the estimated figure of 2.41 B EUR. In the next quarter, revenue is expected to reach 2.64 B EUR.
VX1 net income for the last quarter is 938.92 M EUR, while the quarter before that showed −3.35 B EUR of net income which accounts for 127.99% change. Track more VERTEX PHARMACEUTICAL financial stats to get the full picture.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 1, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICAL on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICAL EBITDA is −79.13 M EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICAL financial statements.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICAL technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICAL stock shows the buy signal. See more of VERTEX PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.